Related Experiment Videos
[Pharmacokinetic and clinical studies on cefdinir fine granules in children]
Insights
Cefdinir (CFDN), a new oral antibiotic, showed high efficacy and safety in children with bacterial infections. The drug demonstrated good clinical responses and no adverse effects in the study group.
Area of Science:
- Pediatric infectious diseases
- Pharmacology and therapeutics
- Antimicrobial agents
Background:
- Bacterial infections are a common concern in pediatric populations.
- The need for effective and safe oral antibiotics in children is ongoing.
- Cephem antibiotics offer a valuable class of treatment options.
Purpose of the Study:
- To evaluate the efficacy and safety of cefdinir (CFDN) in pediatric patients.
- To assess the pharmacokinetic profile of cefdinir in children.
- To determine the clinical utility of CFDN fine granule formulation.
Main Methods:
- A study involving 13 pediatric patients.
- Administration of cefdinir at 3 mg/kg for pharmacokinetic analysis.
- Treatment of bacterial infections with cefdinir fine granule at 9 mg/kg/day.
- Monitoring of plasma concentrations, urinary recovery, clinical responses, and adverse events.
Main Results:
- Cefdinir plasma concentrations peaked at 3-4 hours post-administration (0.57-0.89 microgram/ml).
- Average urinary recovery of cefdinir was 13.4% with significant individual variability.
- An overall efficacy rate of 90.9% was observed in 10 children with 12 bacterial infections.
- No clinical adverse reactions or abnormal laboratory findings were reported.
Conclusions:
- Cefdinir demonstrates promising efficacy and a favorable safety profile for treating bacterial infections in children.
- The pharmacokinetic data suggest adequate absorption and excretion, though with inter-individual variation.
- Cefdinir fine granule is a viable therapeutic option for pediatric bacterial infections.
Abstract:
A new oral cephem, cefdinir (CFDN) was evaluated for its efficacy, safety and pharmacokinetics in 13 children. The results are summarized as follows. Plasma concentration peaked at 3-4 hours after administration of 3 mg/kg of CFDN with Cmax ranging from 0.57-0.89 microgram/ml except 1 case in which the absorption of the drug was poor. Recovery rates in urine averaged at 13.4%, with a large individual variation. Ten children with 12 bacterial infections were treated with 9 mg/kg/day of CFDN fine granule. Clinical responses were good in 10 patients and fair in 1 patient, with an efficacy rate of 90.9%. No clinical adverse reactions nor abnormal laboratory findings were encountered.